and processing date as those that had been administered to the patients with infections. E. cloacae was isolated from all six vials; C. freundii also was isolated from five. The four vials from Florida were from different donors and processing dates than were the vials from Texas. E. coli was isolated from one of two vials from the same cord-blood donor and processing date; E.coli and E. faecalis were isolated from one of two vials from two unique donors with unique processing dates.
Ongoing investigations include active case finding, additional laboratory testing to compare clinical and product isolates, onsite assessments of health care facility infection control and injection safety practices, and investigation of manufacturing practices (including distribution); initial investigation suggests that bacterial contamination occurred before distribution. Umbilical cord blood cannot be decontaminated after collection because there are currently no validated processes for sterilization, so manufacture of derived products must be highly controlled to prevent distribution of contaminated products (4). The Genetech-processed, Liveyon-distributed product is not FDAapproved or lawfully marketed. Though Genetech and Liveyon are registered with FDA, such registration is not a form of FDA approval. FDA registration alone does not demonstrate compliance of firms or their products with the law.
Regardless of when contamination occurred, this investigation highlights the serious potential risks to patients of stem cell therapies administered for unapproved and unproven uses other than hematopoietic or immunologic reconstitution (5) . Although the safety and efficacy of stem cells for other than hematopoietic or immunologic reconstitution have not been well established (1,4), many companies, clinics, and clinicians continue to market products from various sources as treatment for orthopedic, neurologic, and rheumatologic conditions without FDA approval. Such clinics and providers operate in outpatient settings, which often have less robust oversight of infection control measures, including injection safety and medication preparation (6), potentially amplifying risk to patients. Therefore, FDA has recommended that patients avoid receiving such products outside controlled clinical studies being conducted under an investigational new drug application; these settings help ensure that appropriate manufacturing and safety reporting procedures are followed (1). Health care professionals and consumers should report any adverse events related to treatment with the Genetech/Liveyon products or any unapproved stem cell therapies to FDA's MedWatch Safety Information and Adverse Event Reporting Program (https:// www.fda.gov/Safety/MedWatch/). Bloodstream, lumbar epidural abscess 12 * As reported to CDC by health departments. † Abscess and vertebrae were not cultured; both organisms were isolated from blood, and E. faecalis only was isolated from disc space. § No organisms were isolated from skin; both organisms were isolated from blood.
